Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06690190
Active, not recruiting Observational

Artificial Intelligence-based Techniques to Characterize KIdney Microstructure on Histological ImagEs

NCT06690190 · tracked via the Priya Life Science Italy tracker
Sponsor
Mario Negri Institute for Pharmacological Research
Phase
Observational
Started
2024-11-08
Last updated
2024-11-15

Condition(s) studied

End-Stage Renal Disease

Study summary

The primary aim of this observational exploratory study will be to use fully anonymized histological images of kidney human tissue from patients with any kidney disease and normal kidney tissue to develop novel deep learning-based image processing techniques allowing to characterize kidney microstructure across different pathologies and/or disease stages.

Secondly, the study will aim at validating the novel techniques against gold standard (manual) methods, when available, and at developing novel histological imaging biomarkers that could support differential diagnosis, staging of the disease, monitoring of disease progression and response to therapy, and prediction of the disease progression.

Other exploratory aims will include:

* The use of radiomics techniques to identify disease-specific kidney morphology patterns.
* The implementation of uncertainty quantification techniques, able to increase AI explainability.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Any kidney disease or * Healthy kidney Exclusion Criteria: * None

Primary outcome measure(s)

  • Image processing techniques — From image acquisition to study end at 10 years
    Develop novel deep learning-based image processing techniques allowing to characterize kidney microstructure across different pathologies and/or disease stages.

Trial sites (1)

FacilityCityRegionStatus
Clinical Research Centre for Rare Diseases Aldo e Cele Daccò Ranica BG

More Mario Negri Institute for Pharmacological Research trials in Italy

Evaluation of the Quality of Care in the Emergency Department by Studying the Appropriateness of Admissions of Patients Accessing the Emergency Department (ASST Papa Giovanni XXIII) Active, not recruiting
Simulated and Synthetic Health Data: Improving Clinical Research on Rare Diseases. A Real-World Data Simulation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) Trials. A Retrospective, Observational Study Active, not recruiting
Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases Recruiting
Severe Acquired Brain Injuries: Prognostic Factors and Quality of Care Recruiting
Health-care Quality in Semi-intensive Care Units Recruiting

Other trials for the same condition

Xeltis Hemodialysis Access Graft: aXess Pivotal Study Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06690190 on ClinicalTrials.gov ↗ ← All trials in Italy